Board of Directors
James E. Hoyes
Mr. Hoyes began supporting Alitair Pharmaceuticals in late 2016 and was appointed Chief Executive Officer in March 2017. He was also appointed to the Board of Directors in April 2017. He assumed the Chairman of the Board position in March 2019 upon the retirement of Dr. William Howard.
Mr. Hoyes has over 30 years of experience in biopharmaceuticals working on both in industry and in healthcare strategic consulting. He has a proven track record of building high performing teams and delivering consistent year-over-year double-digit revenue growth. Mr. Hoyes has deep experience in building brands, therapeutic areas and companies. He began his career at Sterling Winthrop in sales and earned positions of increasing responsibility in sales management, marketing,strategic marketing and managed care. Mr. Hoyes’s experiences at Sanofi (acquirer of Sterling Winthrop) included work with the launches of Avapro and Plavix and culminated with a position as Vice President, Managed Care. He then joined Elan as Vice President, Marketing which encompassed Neurology, Primary Care and Hospital brands. Mr. Hoyes then joined Serono in 2004 and quickly assumed positions of increasing seniority as EVP, Neurology Therapeutic Area and Chief Commercial Officer. His final position at EMD Serono (US division of Merck Serono) was President and Head of US Operations. This position was the lead of a US organization of over 1,000 employees and gross revenues approaching $2 billion. In 2010, while at EMD Serono, Hoyes was named one of the Top 100 Inspiring People by PharmaVoice.
Mr. Hoyes received his Bachelor of Science degree in Biology from the Pennsylvania State University. In 2004-2005, Mr. Hoyes completed Executive Leadership programs at Sloan School of Management at MIT and The Garvin School of Management at Thunderbird. In 2009- 2010, Mr. Hoyes completed Executive Leadership programs at the Kellogg School of Management at Northwestern, Hong Kong University of Science and Technology, and INSEAD.
Beginning in mid-2018, Mr. Hoyes was engaged by ENDECE (a pre-clinical biopharma company focused in the neuroscience therapeutic area) as a Strategic Advisor to the CEO and he will be joining the Board of Directors of ENDECE in late 2019. Presently, Mr. Hoyes also holds an Executive Partner position with RxC International, a healthcare strategy consulting group.
In addition to this extensive experience in therapeutic area leadership and general management, Mr. Hoyes has served on the boards of PhRMA, BIO (Health Section Governing Board), Mass BIO as well as several charitable organizations.
Mr. Casale is a has over 30 years of healthcare experience. He was the Co-founder and Chief Executive Officer of Scerene Healthcare, a company dedicated to marketing pure and efficacious anti-aging skin care and feminine hygiene products. The assets of Scerene were sold to Enaltus in 2012. Prior to Scerene, Mr. Casale was the Chief Operating Officer of Adams Respiratory Therapeutics. He joined Adams in 2004 as Vice President, Marketing and Business Development and was named Chief Operating Officer in 2006. Mr. Casale was a driving force behind the growth of the Adams business, which grew from $60 million to near $500 million under his leadership. In addition to developing the award winning Mr. Mucus advertising campaign, he led the diversification of the Adams' portfolio of products by launching Mucinex D and DM, Mucinex for Children, Mucinex Nasal Spray. Mr. Casale also led the acquisition of the Delsym brand which nearly doubled in sales in 2 years under his leadership. Adams was sold to Reckitt Benckiser in 2008 for $2.3 billion.
Mr. Casale began his career in 1983 at a Wall Street law firm and joined the legal division of Warner Lambert in 1986. In 1993, he was appointed Warner-Lambert's Vice President of Marketing for the company's upper respiratory and gastrointestinal (GI) consumer products and oversaw several brands, including Benadryl, Sudafed, Zantac 75 and Rolaids. He also served as a global vice president for Warner-Lambert's GI and skin care businesses. Following Warner-Lambert's acquisition by Pfizer Inc., Mr. Casale served as Vice President, Strategic Planning and Business Development for Pfizer's Consumer Healthcare Division.
Mr. Casale currently serves on the Board of PLx Pharma and Daiichi Sankyo, Inc. He was Chairman of Topaz Pharmaceuticals which was sold to Sanofi Aventis in 2011, was on the Board of NextWave Pharmaceuticals which was sold to Pfizer in 2012 and was on the Board of Insight Pharmaceuticals which was sold to Prestige in 2014.
William W. Howard, Ph.D., MBA, is the Founder and past Chairman of the Board of Directors and past President of Alitair Pharmaceuticals. Dr. Howard retired from Alitair in February 2019.
Prior to starting the Company, Dr. Howard served as Senior Vice President of New Products and Business Development for Adams Respiratory Therapeutics, which is best known for the highly successful Mucinex® cough/cold product line. Adams was acquired by Reckitt Benckiser in January 2008 for $2.3 billion, nearly 7 times its fiscal 2007 sales. Dr. Howard first worked for Adams as a consultant in 2001 and later joined Adams in 2004 as a full-time employee after working on the initial commercialization strategy for Mucinex®. After Adams was acquired by global consumer goods powerhouse Reckitt Benckiser, Dr. Howard applied the lessons he learned, which culminated in founding Alitair and developing a strategy to develop a portfolio of products for the prescription market. Following his retirement in February 2019, Dr. Howard has no role on the Board or the Executive Team. Alitair stakeholders and shareholders are grateful to Dr. Howard for his commitment in driving the company forward and to his “Chief Idea Man” status within our sphere of engagement. We all wish Bill well in the future!